A Weight Management Intervention for Overweight Chinese Cancer Survivors
Launched by THE UNIVERSITY OF HONG KONG · Jan 12, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to explore a weight management program specifically designed for Chinese cancer survivors who are struggling with their weight. The main goal is to see if this program can help improve various aspects of health, such as body weight, eating habits, physical activity, and overall quality of life. By participating, you'll help researchers understand how effective this intervention could be for those who have faced cancer.
To be eligible for the trial, you need to be a Chinese cancer survivor who speaks either Cantonese or Mandarin, is at least 18 years old, and has been treated for early-stage cancer. You should also have a body mass index (BMI) of 23 or higher, which means you are considered overweight or obese based on specific guidelines. If you decide to join, you can expect to take part in assessments designed to measure your progress in weight management and overall well-being. Your participation will be invaluable in helping improve support for cancer survivors dealing with weight issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Chinese cancer survivors attending the one-off face-to-face survivorship care clinic
- • who are Cantonese- or Mandarin- speaking
- • aged 18 or above
- • diagnosed with early-stage disease (stage 0-II)
- • have completed primary and adjuvant treatments such as chemotherapy and radiotherapy
- • and with a BMI ≥ 23 kg/m2, as indicative as overweight or obesity using Asia-Pacific BMI cutoffs at 3-months reassessment
- Exclusion Criteria:
- • Non-Chinese survivors with advanced or metastatic disease
- • who have communication difficulties, mobility impairment or cognitive disabilities
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Danielle Ng, PhD
Principal Investigator
School of Public Health, The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported